Marc de Garidel

Marc de Garidel graduated from the École Spéciale des Travaux Publics, an engineering grandes écoles in Paris.[1][3][4] He received business degrees from the Thunderbird School of Global Management in Glendale, Arizona and the Harvard Business School.[1][3][4]

In 1983, he started his career at Eli Lilly and Company, where he worked in France, the United States and Germany.[1][3]

In 1995, he joined Amgen as vice president of finance and treasury for Europe.[1][3][4] In 1998, he became vice president, corporate controller and chief accounting officer of Amgen.[1][3] In 2000, he became vice president and general manager for France, in charge of Amgen France.[1][3] In 2006, he became vice president for Southwestern Europe, including France, Spain, Belgium and Portugal.[1][3] From 2007 to 2010, he served as vice president for Southern Europe, the Middle East, Asia and Latin America at Amgen.[1][3][4]

He has served as chairman and CEO of Ipsen between November 2010 & July 2016.[1][3][4][5] During that period, he led a transformation of Ipsen by concentrating in oncology & neurosciences while launching the blockbuster Somatuline Depot in the United States. He was also responsible for the inlicensing of Cabometyx outside the United States from the biotech company Exelixis.

During that period, He was president and spokesperson for G5 santé, a lobbying group for French pharmaceutical companies, including BioMérieux, Guerbet, Ipsen, the Laboratoire français du Fractionnement et des Biotechnologies, Laboratoires Pierre Fabre, Sanofi, Stallergenes and Laboratoires Théa.[5]

Effective July 18, 2016, Marc de Garidel has assumed the role of Ipsen non-executive chairman and has continued to serve the board of directors through his deep industry expertise. In addition, Marc de Garidel will advise Mayroy, the Ipsen controlling holding company.[6]

In early 2018, Marc de Garidel joined Corvidia Therapeutics, a biotech company based in Waltham,MA,USA. In April 2018, he raised a 60M series B round led by Venrock & other top tier US & Europe venture capital funds. In June 2020, after its lead asset, Ziltivekimab, was near completion of its phase 2b program, the company was acquired for $ 2.1B including an upfront of $725M by Novo Nordisk in one of the largest transaction of the biotech sector in the midst of the Covid19 epidemic.[7]

Marc de Garidel was on the Board of Directors of Corvidia between April 2018 & July 2020.

Marc de Garidel joined AZTherapies as CEO & Board member on Oct 1,2020[8]

He is a Knight in the National Order of the Legion of Honour.